Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aldeyra Therapeutics, Inc.

< Previous 1 2 3 Next >
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Chief Financial Officer Transition
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.